A pharma partnership is the obvious answer. We
Post# of 72440
We can't fund an international phase 3 with our shelf offering or through another Aspire/MFO deal without major dilution. Our daily trading is on the order of $30K-$100K and much of that is suspected to be wash sales. Simply no way to raise $10 million or more with the stock.
Just a matter of 'when' and 'how much' at this point.